2008-08-07T12:26:00
The National Institute for Health and Clinical Excellence has recommended that bevacizumab, sorafenib, sunitinib and temsirolimus should not be treatment options for advanced or metastatic renal cell carcinoma.
With a HSJ subscription you’ll unlock:
HSJ is part of Wilmington Healthcare Limited. Company number 2530185. c/o Wilmington plc, 5th Floor, 10 Whitechapel High Street, London E1 8QS. Registered in England and Wales. Company registration 30158470
Site powered by Webvision Cloud